Rilpivirine Label Highlights Risk In Patients With Higher HIV Levels, Could Limit Use
Lead investigator from Phase III trials says Edurant could be viable option in about half of treatment-naïve patients, points out safety advantages.
Lead investigator from Phase III trials says Edurant could be viable option in about half of treatment-naïve patients, points out safety advantages.